MX368767B - (5,6-dihidro)pirimido[4,5-e]indolizinas. - Google Patents
(5,6-dihidro)pirimido[4,5-e]indolizinas.Info
- Publication number
- MX368767B MX368767B MX2016012997A MX2016012997A MX368767B MX 368767 B MX368767 B MX 368767B MX 2016012997 A MX2016012997 A MX 2016012997A MX 2016012997 A MX2016012997 A MX 2016012997A MX 368767 B MX368767 B MX 368767B
- Authority
- MX
- Mexico
- Prior art keywords
- indolizines
- pyrimido
- dihydro
- cancer
- aryl
- Prior art date
Links
- 150000002478 indolizines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163734 | 2014-04-07 | ||
| EP15153207 | 2015-01-30 | ||
| PCT/EP2015/056839 WO2015155042A1 (en) | 2014-04-07 | 2015-03-30 | (5,6-dihydro)pyrimido[4,5-e]indolizines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016012997A MX2016012997A (es) | 2016-12-07 |
| MX368767B true MX368767B (es) | 2019-10-15 |
Family
ID=52774240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016012997A MX368767B (es) | 2014-04-07 | 2015-03-30 | (5,6-dihidro)pirimido[4,5-e]indolizinas. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9856258B2 (enExample) |
| EP (1) | EP3129374B1 (enExample) |
| JP (1) | JP6518690B2 (enExample) |
| KR (1) | KR102432420B1 (enExample) |
| CN (1) | CN106132963B (enExample) |
| AU (1) | AU2015243694B2 (enExample) |
| BR (1) | BR112016022342B1 (enExample) |
| CA (1) | CA2944610C (enExample) |
| DK (1) | DK3129374T3 (enExample) |
| ES (1) | ES2716165T3 (enExample) |
| HU (1) | HUE043108T2 (enExample) |
| MX (1) | MX368767B (enExample) |
| PL (1) | PL3129374T3 (enExample) |
| PT (1) | PT3129374T (enExample) |
| RU (1) | RU2692479C2 (enExample) |
| WO (1) | WO2015155042A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015155042A1 (en) * | 2014-04-07 | 2015-10-15 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido[4,5-e]indolizines |
| US11208696B2 (en) | 2015-04-17 | 2021-12-28 | Netherlands Translational Research Center B.V. | Prognostic biomarkers for TTK inhibitor chemotherapy |
| ES2858753T3 (es) * | 2016-02-19 | 2021-09-30 | Phoenix Molecular Designs | Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer |
| CN109311848B (zh) | 2016-06-07 | 2022-02-01 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| CN106551938B (zh) * | 2016-11-26 | 2017-11-24 | 广东安诺药业股份有限公司 | 一种治疗非酒精性脂肪肝的药物及其应用 |
| SMT202400385T1 (it) | 2017-03-23 | 2024-11-15 | Jacobio Pharmaceuticals Co Ltd | Nuovi derivati eterociclici utili come inibitori di shp2 |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| EP3924352A4 (en) | 2019-02-11 | 2022-11-16 | Phoenix Molecular Designs | CRYSTALLINE FORMS OF AN RSK INHIBITOR |
| KR20240107189A (ko) * | 2021-12-15 | 2024-07-08 | 신라젠(주) | 신생물성 질환 치료에 사용하기 위한 약제학적 병용물 |
| AU2022408915A1 (en) * | 2021-12-15 | 2024-06-27 | Sillajen, Inc. | Methods of treating neoplastic diseases |
| US20250049926A1 (en) * | 2021-12-15 | 2025-02-13 | Sillajen, Inc. | Pharmaceutical compositions comprising modified betacyclodextrins |
| AU2023228543A1 (en) * | 2022-03-04 | 2024-08-22 | Sillajen, Inc. | Pharmaceutical combinations for use in the treatment of neoplastic diseases. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002337142B2 (en) * | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
| US7482354B2 (en) | 2003-05-22 | 2009-01-27 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| EP2118102B1 (en) | 2006-11-28 | 2013-06-12 | Nerviano Medical Sciences S.r.l. | Tricyclic indoles and (4,5-dihydro) indoles |
| HRP20160243T1 (hr) * | 2008-06-26 | 2016-04-08 | Les Laboratoires Servier | Pirazolo-kinazolini kao modulatori aktivnosti protein kinaze |
| WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| CN102428086B (zh) | 2009-04-29 | 2014-08-20 | 内尔维阿诺医学科学有限公司 | Cdk抑制剂的盐类 |
| CN103626777B (zh) | 2009-07-29 | 2015-10-21 | 内尔维阿诺医学科学有限公司 | Plk抑制剂的盐类 |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| US20130303532A1 (en) * | 2010-12-17 | 2013-11-14 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| BR112013018515B1 (pt) * | 2011-01-26 | 2021-06-29 | Nerviano Medical Sciences S.R.I | Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase |
| JP6523267B2 (ja) | 2013-06-24 | 2019-05-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用 |
| WO2015155042A1 (en) * | 2014-04-07 | 2015-10-15 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido[4,5-e]indolizines |
-
2015
- 2015-03-30 WO PCT/EP2015/056839 patent/WO2015155042A1/en not_active Ceased
- 2015-03-30 RU RU2016141405A patent/RU2692479C2/ru active
- 2015-03-30 CN CN201580017365.8A patent/CN106132963B/zh active Active
- 2015-03-30 US US15/128,874 patent/US9856258B2/en not_active Ceased
- 2015-03-30 DK DK15712912.3T patent/DK3129374T3/en active
- 2015-03-30 PL PL15712912T patent/PL3129374T3/pl unknown
- 2015-03-30 PT PT15712912T patent/PT3129374T/pt unknown
- 2015-03-30 JP JP2016560952A patent/JP6518690B2/ja active Active
- 2015-03-30 BR BR112016022342-0A patent/BR112016022342B1/pt active IP Right Grant
- 2015-03-30 CA CA2944610A patent/CA2944610C/en active Active
- 2015-03-30 AU AU2015243694A patent/AU2015243694B2/en active Active
- 2015-03-30 US US16/728,900 patent/USRE48974E1/en active Active
- 2015-03-30 US US17/579,990 patent/USRE50082E1/en active Active
- 2015-03-30 MX MX2016012997A patent/MX368767B/es active IP Right Grant
- 2015-03-30 ES ES15712912T patent/ES2716165T3/es active Active
- 2015-03-30 HU HUE15712912A patent/HUE043108T2/hu unknown
- 2015-03-30 EP EP15712912.3A patent/EP3129374B1/en active Active
- 2015-03-30 KR KR1020167031029A patent/KR102432420B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170013866A (ko) | 2017-02-07 |
| RU2016141405A3 (enExample) | 2018-10-02 |
| BR112016022342A8 (pt) | 2021-07-20 |
| PT3129374T (pt) | 2019-03-25 |
| BR112016022342A2 (pt) | 2017-08-15 |
| EP3129374A1 (en) | 2017-02-15 |
| MX2016012997A (es) | 2016-12-07 |
| RU2692479C2 (ru) | 2019-06-25 |
| JP2017510595A (ja) | 2017-04-13 |
| DK3129374T3 (en) | 2019-04-08 |
| US20170096432A1 (en) | 2017-04-06 |
| WO2015155042A1 (en) | 2015-10-15 |
| ES2716165T3 (es) | 2019-06-10 |
| JP6518690B2 (ja) | 2019-05-22 |
| USRE50082E1 (en) | 2024-08-20 |
| CA2944610A1 (en) | 2015-10-15 |
| HUE043108T2 (hu) | 2019-07-29 |
| AU2015243694B2 (en) | 2019-01-17 |
| CN106132963B (zh) | 2019-08-06 |
| AU2015243694A1 (en) | 2016-11-03 |
| USRE48974E1 (en) | 2022-03-15 |
| CN106132963A (zh) | 2016-11-16 |
| RU2016141405A (ru) | 2018-05-07 |
| CA2944610C (en) | 2024-01-09 |
| EP3129374B1 (en) | 2018-12-19 |
| KR102432420B1 (ko) | 2022-08-17 |
| PL3129374T3 (pl) | 2019-07-31 |
| BR112016022342B1 (pt) | 2022-10-04 |
| US9856258B2 (en) | 2018-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX368767B (es) | (5,6-dihidro)pirimido[4,5-e]indolizinas. | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| CA2999253C (en) | Heterocyclic compounds and uses thereof | |
| PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
| EA033266B1 (ru) | Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| JO3195B1 (ar) | مشتقات أندوليزين جديدة, وطريقة تحضيرهم والتركيبات الصيدلانية التي تحتوي عليهم لعلاج السرطان | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
| TN2017000524A1 (en) | New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| MY190243A (en) | Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| EP3597649B8 (en) | Compositions containing substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors | |
| MD20160136A2 (ro) | Compuşi dihidroizochinolinonici substituiţi | |
| JO3275B1 (ar) | مشتقات بيرول جديدة وطريقة لتحضيرها وتركيبات صيدلانية التي تحتوي عليها | |
| MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
| MX362215B (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
| EP3250572A4 (en) | Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | |
| MY191628A (en) | Novel triazolo[4,5-d]pyrimidine derivatives | |
| JO3310B1 (ar) | مشتقات إندوليزين جديدة وطريقة لإنتاجها وتركيبات صيدلانية تحتوي عليها | |
| TN2015000262A1 (en) | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors | |
| AU2015352440B2 (en) | Compounds | |
| CY1120602T1 (el) | [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων | |
| PH12017500342B1 (en) | 7 - (morpholinyl) -2- (n-piperazinyl) methyl thieno [2,3-c] pyridine derivatives as anticancer drugs | |
| PH12016501997A1 (en) | Cycloalkyl-linked diheterocycle derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |